Request an Appointment



Contact us with Questions

Expand Content

Journal Publications

Heart and Vascular Institute Publications 2010 - Present

We have included a selection of our staff physician journal publications from 2010 through December 2014. This is not a complete list. We have chosen journal articles based on the impact this journal has on the medical field as well as noted by our staff to be most utilized by their specialty.

American Heart Journal


Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, Lopes RD, Green CL, Lincoff AM, Armstrong PW, Roe MT. Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J. 2014 Oct;168(4):503-511. [PM:25262260]

Cavalcante JL, Marwick TH, Hachamovitch R, Popovic ZB, Aldweib N, Starling RC, Desai MY, Flamm SD, Kwon DH. Is there a role for diastolic function assessment in era of delayed enhancement cardiac magnetic resonance imaging?: A multimodality imaging study in patients with advanced ischemic cardiomyopathy. Am Heart J. 2014 Aug;168(2):220-228. [PM:25066562]

Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K, Jolicoeur ME, Mahaffey KW, White H, Wang TY. Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2014 Aug;168(2):189-196. [PM:25066558]

Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca MI, Vardas PE, Kirchhof P, Hohnloser SH, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. Am Heart J. 2014 May;167(5):646-652. [PM:24766973]

Whitlock R, Teoh K, Vincent J, Devereaux PJ, Lamy A, Paparella D, Zuo Y, Sessler DI, Shah P, Villar JC, Karthikeyan G, Urrutia G, Alvezum A, Zhang X, Abbasi SH, Zheng H, Quantz M, Yared JP, Yu H, Noiseux N, Yusuf S. Rationale and design of the Steroids in Cardiac Surgery trial. Am Heart J. 2014 May;167(5):660-665. [PM:24766975]


Aldweib N, Negishi K, Seicean S, Jaber WA, Hachamovitch R, Cerqueira M, Marwick TH. Appropriate test selection for single-photon emission computed tomography imaging: Association with clinical risk, posttest management, and outcomes. Am Heart J. 2013 Sep;166(3):581-588. [PM:24016510]

Hsich EM, Grau-Sepulveda MV, Hernandez AF, Eapen ZJ, Xian Y, Schwamm LH, Bhatt DL, Fonarow GC. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: Findings from the Get With The Guideline-Heart Failure Registry. Am Heart J. 2013 Dec;166(6):1063-1071. [PM:24268222]

Kobayashi T, Popovic Z, Bhonsale A, Smedira NG, Tan C, Rodriguez ER, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy. Am Heart J. 2013 Sep;166(3):503-511. [PM:24016500]

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Ryden L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. Am Heart J. 2013 Sep;166(3):429-434. [PM:24016490]

Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, Cho L. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J. 2013 Sep;166(3):597-603. [PM:24016512]

Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JFE, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823-830. [PM:24176437]


De S, Borowski AG, Wang H, Nye L, Xin B, Thomas JD, Tang WHW. Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. Am Heart J. 2011 Aug;162(2):262-267. [PM:21835286]


Rader F, Van Wagoner DR, Gillinov AM, Blackstone EH. Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery. Am Heart J. 2010 Aug;160(2):329-336.e1.

American Journal of Cardiology


Alraies MC, Al Jaroudi W, Shabrang C, Yarmohammadi H, Klein AL, Tamarappoo BK. Clinical features associated with adverse events in patients with post-pericardiotomy syndrome following cardiac surgery. Am J Cardiol. 2014 Nov 1;114(9):1426-1430. [PM:25306427]

Beohar N, Zajarias A, Thourani VH, Herrmann HC, Mack M, Kapadia S, Green P, Arnold SV, Cohen DJ, Genereux P, Xu K, Leon MB, Kirtane AJ. Analysis of early out-of hospital mortality after transcatheter aortic valve implantation among patients with aortic stenosis successfully discharged from the hospital and alive at 30 days (from the Placement of Aortic Transcatheter Valves Trial). Am J Cardiol. 2014 Nov 15;114(10):1550-1555. [PM:25277334]

Kunadian V, Mehran R, Lincoff AM, Feit F, Manoukian SV, Hamon M, Cox DA, Dangas GD, Stone GW. Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2014 Dec 15;114(12):1823-1829. [PM:25438908]

Mani P, Uno K, St John J, Tuzcu EM, Nissen SE, Nicholls SJ